Purchase Order 75N91020P00990

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

The U.S. government awarded a $28,610 firm fixed-price purchase order to Innomics Inc. for 400 DNA sequencing samples. The contract was issued on August 16, 2016, with an ultimate completion date of January 31, 2018. Work was performed in Cambridge, Massachusetts. No set-aside designation was applied to this award. Innomics Inc. is a for-profit corporation specializing in genomic sequencing and bioinformatics services to federal agencies. The company has established expertise across multiple...

The U.S. government awarded a firm fixed-price purchase order to Innomics Inc. for the provision of 100 units of package library and sequencing services, with a ceiling value of $15,160. The award was issued on October 9, 2019, with an ultimate completion date of December 9, 2019. The work will be performed in Cambridge, Massachusetts, and the contract involves no set-aside designation. Innomics Inc., a for-profit corporation specializing in genomic sequencing and bioinformatics services, was...

The U.S. government awarded a $31,440 firm fixed-price purchase order to Innomics Inc. for whole genome resequencing services. The contract was awarded on September 16, 2017, with an ultimate completion date of November 17, 2017, and will be performed at the contractor's facility in Cambridge, Massachusetts. No set-aside designation was used for this procurement. Innomics Inc., a for-profit genomic sequencing and bioinformatics services provider, was selected to deliver this specialized...

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 17, 2018, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price pricing structure and an ultimate completion date of September 15, 2018. Illumina manufactures advanced DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute issued a purchase order to The Broad Institute, Inc. for $13,480.01 on January 24, 2019, for custom lab work on a genomics platform. Work is performed in Cambridge, Massachusetts. The order is firm fixed-price with an ultimate completion date of July 25, 2019. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on June 20, 2018, for genetic sequencing and genomic analysis technologies. Place of performance is Bethesda, MD. Ultimate completion date is July 19, 2018.</p> <p>The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $22,646 purchase order to Illumina, Inc. for service agreement on a NovaSeq 6000 sequencer. The firm fixed price contract runs from December 1, 2023 through January 17, 2024 and will be performed in Rockville, Maryland. This purchase order provides sequencing services utilizing Illumina's NovaSeq 6000 platform to support the National Cancer Institute's cancer research efforts. No major...